



Repurchase of C-RAD B-shares in week 33, 2023

During 15 August 2023 and 18 August 2023, C-RAD AB (publ) (LEI code 549300SPXLHF15W2CU25), has repurchased in total 60,000 own B-shares (ISIN: SE0002016352).

The repurchase is carried out in accordance with the Annual General Meeting's authorization to the Board to acquire shares in the Company. The purpose of the repurchase is to cover the Company's obligations under previously resolved incentive programs.

Date:	Aggregated daily volume (number of shares):	Weighted average share price per day (SEK):	Total daily transaction value (SEK):
2023-08-15	11,710	31.7548	371,848.7
2023-08-16	17,000	31.4513	534,672.1
2023-08-17	16,290	30.9886	504,804.3
2023-08-18	15,000	30.2481	453,721.5
Total:	60,000	31.0841	1,865,046.6

All acquisitions have been carried out on Nasdaq Stockholm by Pareto on behalf of C-RAD. Following the above acquisitions, C-RAD AB holds a total of 60,000 class B-shares in treasury as per 18 August 2023, equivalent to 0.18 percent of the total number of shares outstanding, and 0.14 percent of the votes. The total number of shares outstanding in C-RAD AB, including shares held in treasury, is 33,766,935, where of 862,887 are Class A-shares and 32,904,048 are Class B-shares.

For further information:

Cecilia de Leeuw, CEO, +46 (0)795 85 66 77, investors@c-rad.com
Christoffer Herou, CFO, +46 (0)725 82 86 16, investors@c-rad.com

Press Release
21 August 2023 12:30:00 CEST



About C-RAD

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD. Inspiring excellence in cancer treatment.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit <http://www.c-rad.com>

Attachments

[Repurchase of C-RAD B-shares in week 33, 2023](#)